Molecular Therapy: Methods & Clinical Development (Dec 2022)

Neutralization of the adaptor protein PAG by monoclonal antibody limits murine tumor growth

  • Marianne Strazza,
  • Emily K. Moore,
  • Kieran Adam,
  • Inbar Azoulay-Alfaguter,
  • Adam Mor

Journal volume & issue
Vol. 27
pp. 380 – 390

Abstract

Read online

The transmembrane adaptor phosphoprotein associated with glycosphingolipid-enriched microdomains 1 (PAG) is phosphorylated in T cells downstream of PD-1 signaling and contributes to the resulting functional inhibition of multiple cellular processes. Furthermore, PAG expression is negatively correlated with survival in multiple human tumors and is a driver of murine tumor growth and immune evasion. Here we develop an antibody that targets the extracellular domain of human PAG, with cross-reactivity to murine PAG. We demonstrate that this antibody binds to extracellular PAG on intact cells and affects T cell activation. Finally, we show that administration of anti-PAG monoclonal antibody in combination with anti-PD-1 antibody to mice bearing MC38 tumors limited tumor growth and enhanced T cell infiltration to tumors.

Keywords